Literature DB >> 11317223

Evidence for association of the myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples.

T Yoshikawa1, M Kikuchi, K Saito, A Watanabe, K Yamada, H Shibuya, M Nankai, A Kurumaji, E Hattori, H Ishiguro, H Shimizu, Y Okubo, M Toru, S D Detera-Wadleigh.   

Abstract

In our search for candidate genes for affective disorder on the short arm of chromosome 18, we cloned IMPA2, a previously unreported myo-inositol monophosphatase gene, that maps to 18p11.2. We determined its genomic structure and detected three new single nucleotide polymorphisms (SNPs). In the present study, we screened the gene further to search for additional polymorphisms in Japanese samples and identified seven other SNPs, including a novel missense mutation. These polymorphisms clustered into three regions of the gene. Three relatively informative SNPs, 58G>A, IVS1--15G>A and 800C>T from clusters 1, 2 and 3, respectively, were selected for association tests using a case-control design. The Japanese cohort included 302 schizophrenics, 205 patients with affective disorder and 308 controls. Genotyping was done either by melting curve analysis on the LightCycler or by sequencing. All three SNPs showed significant genotypic association (nominal P = 0.031--0.0001) with schizophrenia, but not with affective disorder. These findings increase the relevance of 18p11.2 to schizophrenia susceptibility because GNAL, which has been shown previously to be implicated in schizophrenia in an independent study, is in close physical proximity to IMPA2. Our findings suggest that IMPA2 or a gene nearby may contribute to the overall genetic risk for schizophrenia among Japanese.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317223     DOI: 10.1038/sj.mp.4000835

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  8 in total

Review 1.  Bipolar disorder and schizophrenia: convergent molecular data.

Authors:  Wade Berrettini
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

2.  Bipolar disorder and schizophrenia: not so distant relatives?

Authors:  Wade Berrettini
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

3.  Identification of candidate genes associated with bacterial and viral infections in wild boars hunted in Tuscany (Italy).

Authors:  M C Fabbri; A Crovetti; L Tinacci; F Bertelloni; A Armani; M Mazzei; F Fratini; R Bozzi; F Cecchi
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

4.  Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis.

Authors:  Tetsuo Ohnishi; Takuya Murata; Akiko Watanabe; Akiko Hida; Hisako Ohba; Yoshimi Iwayama; Kazuo Mishima; Yoichi Gondo; Takeo Yoshikawa
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

5.  Ca2+ Influx through Store-operated Calcium Channels Replenishes the Functional Phosphatidylinositol 4,5-Bisphosphate Pool Used by Cysteinyl Leukotriene Type I Receptors.

Authors:  Abdullah Alswied; Anant B Parekh
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

6.  A promoter polymorphism rs2075824 within IMPA2 gene affecting the transcription activity: possible relationship with schizophrenia.

Authors:  Jia Li; Sheng Huang; Hui-Rong Dai; Juan Wang; Li-Hui Lin; Hui Xiao; Xia Peng; Fei Li; Yu-Ping Wang; Jian-Min Yuan; Li Li
Journal:  J Cell Mol Med       Date:  2016-10-17       Impact factor: 5.310

7.  Two novel genomic regions associated with fearfulness in dogs overlap human neuropsychiatric loci.

Authors:  R Sarviaho; O Hakosalo; K Tiira; S Sulkama; E Salmela; M K Hytönen; M J Sillanpää; H Lohi
Journal:  Transl Psychiatry       Date:  2019-01-17       Impact factor: 6.222

8.  IMPA2 polymorphisms and risk of ischemic stroke in a northwest Han Chinese population.

Authors:  Qiaoya Ma; Ying Yang; Yuyan Na; Tianbo Jin; Yidong Xue; Yuting Shi; Chen Li; Wanggang Zhang
Journal:  Oncotarget       Date:  2016-11-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.